Entera Bio names Riccardo Paolo Camisasca chief medical officer

Reuters2026/08/18 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Entera Bio named Riccardo Paolo Camisasca as chief medical officer ahead of its planned EB613 Phase 3 initiation.
Camisasca most recently served as global head of R&D at Sumitomo Pharma Switzerland, overseeing clinical development and global trial execution.
He previously held clinical development and medical affairs leadership roles at Bial, Syneos Health, Takeda, Novartis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180800PRIMZONEFULLFEED9811965) on August 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Entera Bio names Riccardo Paolo Camisasca chief medical officer

You may also like

Crypto prices